heart failure – recorded their progress by filling out the self-reported Kansas City Cardiomyopathy Questionnaire (KCCQ) on their smartphone. Participants who received Invokana reported ...

The dual-primary endpoints for the trial were to examine changes from baseline in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-23 CSS) and peak oxygen consumption (pVO2 ...

It also missed the mark in two exploratory outcome measures – the change from baseline in NT-pro BNP – a peptide released from the walls of the heart when it is overloaded – and the KCCQ ...

In a communication on April 14, 2025, Bristol Myers Squibb said mavacamten did not meet its dual primary endpoints of changes in the Kansas City Cardiomyopathy Questionnaire clinical summary score ...

The dual-primary endpoints for the trial were to examine changes from baseline in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-23 CSS) and peak oxygen consumption (pVO2 ...

did not meet its dual primary endpoints of changes from baseline to Week 48 compared to placebo in the Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-23 CSS) and peak ...

The trial did not meet its dual primary endpoints of changes from baseline to Week 48 compared to placebo in the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score (KCCQ-23 CSS ...